Xtant Medical (NYSEAMERICAN:XTNT) Share Price Crosses Above Two Hundred Day Moving Average – What’s Next?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)’s share price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.51. Xtant Medical shares last traded at $0.51, with a volume of 79,203 shares changing hands.

Xtant Medical Stock Performance

The company has a market capitalization of $66.72 million, a P/E ratio of -3.69 and a beta of 0.35. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.12 and a quick ratio of 0.88. The company’s fifty day moving average is $0.53.

Institutional Investors Weigh In On Xtant Medical

An institutional investor recently raised its position in Xtant Medical stock. Geode Capital Management LLC boosted its holdings in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 70.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 515,006 shares of the medical device company’s stock after acquiring an additional 212,394 shares during the quarter. Geode Capital Management LLC owned 0.37% of Xtant Medical worth $348,000 at the end of the most recent quarter. 69.33% of the stock is owned by institutional investors and hedge funds.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.